RVMD

Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc. (RVMD) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A+); its weakest is Value (D+). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
D+
Factor Score 1.8 / 5.0
Growth
A+
Factor Score 4.5 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -55.6
EV / EBITDA -20.8
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -18.7%
Price Return 12M 161.7%
Catalyst Signal 0.00
Market Cap $37.3B
TTM Revenue $197.6M
Price / Sales 188.6
ROE -93.6%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 D+ (1.8) A+ (4.5) C- (2.0) B- (3.1) C+ (2.6) C+ (2.8)
2026-11-07 C+ (2.5) B (3.3) D+ (1.8) B- (3.1) C+ (2.7) C+ (2.7)
2026-10-31 C+ (2.5) B (3.2) D+ (1.8) B (3.3) C+ (2.7) C+ (2.7)
2026-10-24 C+ (2.5) B- (3.1) D+ (1.8) B- (3.1) C+ (2.6) C+ (2.6)
2026-10-17 C+ (2.5) B- (3.1) D+ (1.8) B- (3.0) C+ (2.6) C+ (2.6)
Page 1 of 6